Marina Posts Drop in Q2 Losses

Premium

Marina Biotech, formerly MDRNA, reported this month a drop in second-quarter losses amid a 12 percent declined in expenses.

For the three-month period ended June 30, Marina's net loss fell to $4.1 million, or $0.34 per share, from a year-ago loss of $7.5 million, or $0.84 per share.

Revenues in the quarter slipped to $200,000 from $300,000, but this decrease was more than offset by a dip in research and development spending to $7.4 million from $8.5 million. Selling, general, and administrative costs, however, rose 10 percent to $4.8 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

A direct-to-consumer genetic testing company sent out used spit kits, CNBC reports.

Nature News reports that some developers are nervous about GitHub's acquisition by Microsoft.

In PLOS this week: comparison of commercial bisulfite kits, new method to predict essential proteins, and more

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.